{"title":"肺癌患者血清胃泌素释放肽前体（ProGRP）和神经元特异性烯醇化酶（NSE）水平的诊断价值和治疗效果。","authors":"Ping Wang, Mingjie Yu","doi":"10.5937/jomb0-50852","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary lung cancer is one of the most prevalent malignant tumours in China. Small cell lung cancer (SCLC) is a highly malignant, undifferentiated tumour prone to metastasis and is usually diagnosed in its middle or late stages. Pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) tumour markers are recommended in the literature for early diagnosis. Objective: The purpose of this research is to probe the diagnostic value and therapeutic efficacy of serum levels of ProGRP and NSE in SCLC to enhance the level of clinical diagnosis.</p><p><strong>Methods: </strong>A total of 84 SCLC patients who were admitted to our hospital from December 2022 to March 2024 were included in the SCLC group. The NSCLC group consisted of 45 patients diagnosed with NSCLC, while the benign lung disease group consisted of 57 patients diagnosed with non-cancerous lung conditions. Furthermore, the healthy control group comprised 60 healthy individuals. The serum levels of ProGRP and NSE were compared across all four groups.</p><p><strong>Results: </strong>The SCLC group exhibited considerably elevated serum ProGRP and NSE levels compared to the healthy control group, benign lung disease group, and NSCLC group (P< 0.05). ProGRP and NSE values were higher in limited-stage SCLC than in extensive-stage SCLC (P < 0.05). The ROC curve displayed that the critical value of ProGRP for diagnosing SCLC was 136.49 pg/mL, the area under the curve (AUC) was 0.869, the sensitivity attained 80.00%, and the specificity reached 84.87%, indicating a better diagnostic efficacy than that of NSE (P< 0.05).</p><p><strong>Conclusions: </strong>The tumour markers ProGRP and NSE levels are of paramount significance for the clinical diagnosis and staging of SCLC patients. ProGRP is a more specific and sensitive tumour marker for SCLC than NSE and can be employed as an auxiliary diagnostic tool for SCLC. Thus, it is worth promoting ProGRP in a clinical setting.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"945-954"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433308/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diagnostic value and therapeutic efficacy of serum levels of pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) in patients with lung cancer.\",\"authors\":\"Ping Wang, Mingjie Yu\",\"doi\":\"10.5937/jomb0-50852\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Primary lung cancer is one of the most prevalent malignant tumours in China. Small cell lung cancer (SCLC) is a highly malignant, undifferentiated tumour prone to metastasis and is usually diagnosed in its middle or late stages. Pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) tumour markers are recommended in the literature for early diagnosis. Objective: The purpose of this research is to probe the diagnostic value and therapeutic efficacy of serum levels of ProGRP and NSE in SCLC to enhance the level of clinical diagnosis.</p><p><strong>Methods: </strong>A total of 84 SCLC patients who were admitted to our hospital from December 2022 to March 2024 were included in the SCLC group. The NSCLC group consisted of 45 patients diagnosed with NSCLC, while the benign lung disease group consisted of 57 patients diagnosed with non-cancerous lung conditions. Furthermore, the healthy control group comprised 60 healthy individuals. The serum levels of ProGRP and NSE were compared across all four groups.</p><p><strong>Results: </strong>The SCLC group exhibited considerably elevated serum ProGRP and NSE levels compared to the healthy control group, benign lung disease group, and NSCLC group (P< 0.05). ProGRP and NSE values were higher in limited-stage SCLC than in extensive-stage SCLC (P < 0.05). The ROC curve displayed that the critical value of ProGRP for diagnosing SCLC was 136.49 pg/mL, the area under the curve (AUC) was 0.869, the sensitivity attained 80.00%, and the specificity reached 84.87%, indicating a better diagnostic efficacy than that of NSE (P< 0.05).</p><p><strong>Conclusions: </strong>The tumour markers ProGRP and NSE levels are of paramount significance for the clinical diagnosis and staging of SCLC patients. ProGRP is a more specific and sensitive tumour marker for SCLC than NSE and can be employed as an auxiliary diagnostic tool for SCLC. Thus, it is worth promoting ProGRP in a clinical setting.</p>\",\"PeriodicalId\":16175,\"journal\":{\"name\":\"Journal of Medical Biochemistry\",\"volume\":\"44 5\",\"pages\":\"945-954\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433308/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5937/jomb0-50852\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-50852","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Diagnostic value and therapeutic efficacy of serum levels of pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) in patients with lung cancer.
Background: Primary lung cancer is one of the most prevalent malignant tumours in China. Small cell lung cancer (SCLC) is a highly malignant, undifferentiated tumour prone to metastasis and is usually diagnosed in its middle or late stages. Pro-gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) tumour markers are recommended in the literature for early diagnosis. Objective: The purpose of this research is to probe the diagnostic value and therapeutic efficacy of serum levels of ProGRP and NSE in SCLC to enhance the level of clinical diagnosis.
Methods: A total of 84 SCLC patients who were admitted to our hospital from December 2022 to March 2024 were included in the SCLC group. The NSCLC group consisted of 45 patients diagnosed with NSCLC, while the benign lung disease group consisted of 57 patients diagnosed with non-cancerous lung conditions. Furthermore, the healthy control group comprised 60 healthy individuals. The serum levels of ProGRP and NSE were compared across all four groups.
Results: The SCLC group exhibited considerably elevated serum ProGRP and NSE levels compared to the healthy control group, benign lung disease group, and NSCLC group (P< 0.05). ProGRP and NSE values were higher in limited-stage SCLC than in extensive-stage SCLC (P < 0.05). The ROC curve displayed that the critical value of ProGRP for diagnosing SCLC was 136.49 pg/mL, the area under the curve (AUC) was 0.869, the sensitivity attained 80.00%, and the specificity reached 84.87%, indicating a better diagnostic efficacy than that of NSE (P< 0.05).
Conclusions: The tumour markers ProGRP and NSE levels are of paramount significance for the clinical diagnosis and staging of SCLC patients. ProGRP is a more specific and sensitive tumour marker for SCLC than NSE and can be employed as an auxiliary diagnostic tool for SCLC. Thus, it is worth promoting ProGRP in a clinical setting.
期刊介绍：
The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly.
The Journal publishes original scientific and specialized articles on all aspects of
clinical and medical biochemistry,
molecular medicine,
clinical hematology and coagulation,
clinical immunology and autoimmunity,
clinical microbiology,
virology,
clinical genomics and molecular biology,
genetic epidemiology,
drug measurement,
evaluation of diagnostic markers,
new reagents and laboratory equipment,
reference materials and methods,
reference values,
laboratory organization,
automation,
quality control,
clinical metrology,
all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
